Crystal structure of givinostat hydrochloride monohydrate Form I, C 24 H 28 N 3 O 4 Cl(H 2 O)
Source abstract
Abstract
Abstract The crystal structure of givinostat hydrochloride monohydrate Form I has been solved and refined using synchrotron X-ray powder diffraction data and optimized using density functional theory techniques. Givinostat hydrochloride monohydrate Form I crystallizes in the space group P2 1 (#4) with a = 7.98657(17), b = 8.20633(10), c = 18.2406(6) Å, β = 98.1069(13)°, V = 1,183.55(4) Å 3 , and Z = 2 at 298 K. The crystal structure consists of layers of cations and anions/water molecules parallel to the ab -plane. The cations stack along the a -axis, with the phenyl and naphthalene rings alternating in the stacks. Hydrogen bonds link the cations, anions, and water molecules in two-dimensional networks parallel to the ab -plane. The powder pattern has been submitted to the International Centre for Diffraction Data for inclusion in the Powder Diffraction File ™ (PDF ® ).
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Crystal structures of chemical compounds · Crystallography and molecular interactions · X-ray Diffraction in Crystallography
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Illinois Institute of Technology
North Central College
International Centre for Diffraction Data (ICDD)
Funding
International Centre for Diffraction Data
References (34)
Show source-provided references
1. 2024
2. 10.1107/S205252061600395410.1107/S2052520616003954 ↗
3. Bertolini, G. , Biffi, M. , Leoni, F. , Mizrahi, J. , Pavich, G. , and Mascagni, P. . 2000. “Compounds with Anti-Inflammatory and Immunosuppressive Activities.” U.S. Patent 6034096.
4. 10.1017/S088571562400015010.1017/S0885715624000150 ↗
5. 10.1021/ar00172a00510.1021/ar00172a005 ↗
6. 10.1007/BF0054909610.1007/BF00549096 ↗
7. 2023
8. 10.1107/S205252061402290210.1107/S2052520614022902 ↗
9. 10.1107/S002188981101462210.1107/S0021889811014622 ↗
10. Turchetta, S. , and Zenoni, M. . 2011. “Novel Polymorph of the Hydrochloride of the 4-Hydroxycarbamoylphenyl)-Carbamic Acid (6-Diethylaminomethylnaphtalen-2-Yl) Ester.” International Patent Application WO 2011/092556 A1.
11. 2023
12. 2013
13. 10.1021/ci049780b10.1021/ci049780b ↗
14. 10.1107/S160057671901409210.1107/S1600576719014092 ↗
15. 10.1107/S160057752100249610.1107/S1600577521002496 ↗
16. Bravais · 1866
17. 2024
18. 10.1107/S002188989800600110.1107/S0021889898006001 ↗
19. 10.1002/anie.19951555110.1002/anie.199515551 ↗
20. 10.1063/1.46788210.1063/1.467882 ↗
21. 10.1021/acs.jctc.2c0095810.1021/acs.jctc.2c00958 ↗
22. 10.1016/0927-0256(96)00008-010.1016/0927-0256(96)00008-0 ↗
23. 10.1002/jcc.2315310.1002/jcc.23153 ↗
24. 10.1107/S160057672100291010.1107/S1600576721002910 ↗
25. 10.1093/nar/gkac95610.1093/nar/gkac956 ↗
26. Pinori, M. , and Mascagni, P. . 2008. “Monohydrate Hydrochloride of the 4-Hydroxycarbamoylphenyl)-Carbamic Acid (6-Diethylaminomethylnaphtalen-2-Yl) Ester.” U.S. Patent 7329689 B2.
27. 10.3406/bulmi.1907.282010.3406/bulmi.1907.2820 ↗
28. 10.1107/S002188981301311310.1107/S0021889813013113 ↗
29. A New Law of Crystal Morphology Extending the Law of Bravais
30. 10.1107/S010876810000723010.1107/S0108768100007230 ↗
31. 10.1017/S088571561400051710.1017/S0885715614000517 ↗
32. 10.1017/S088571561800082910.1017/S0885715618000829 ↗
33. 2023
34. 10.1107/S002188981300353110.1107/S0021889813003531 ↗